Article in Science translational medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
12 authors.
Stefan RadtkeStem Cell and Gene Therapy Program, Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0002-2842-4820
Emily FieldsStem Cell and Gene Therapy Program, Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-7352-5260
Kyle SwingStem Cell and Gene Therapy Program, Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0007-1808-7609
Greta KanestromStem Cell and Gene Therapy Program, Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0007-0494-7823
Jonathan S YenDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0002-9432-9450
Dnyanada PandeStem Cell and Gene Therapy Program, Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-9343-0584
Mark R EnstromStem Cell and Gene Therapy Program, Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Olivier HumbertStem Cell and Gene Therapy Program, Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0009-0003-1320-9030
Mitchell J WeissDepartment of Hematology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.ORCID 0000-0003-2460-3036
David R LiuMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.ORCID 0000-0002-9943-7557
Gregory A NewbyMerkin Institute of Transformative Technologies in Healthcare, Broad Institute of Harvard and MIT, Cambridge, MA 02142, USA.ORCID 0000-0001-7869-2615
Hans-Peter KiemStem Cell and Gene Therapy Program, Translational Science and Therapeutics, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.ORCID 0000-0001-5949-4947
Funding
Translational Bioimaging Core Shared ResourceP30CA015704 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Eric Collisson · 1985 to 2026
$296.4M
Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Washington National Primate Research CenterP51OD010425 · OD · UNIVERSITY OF WASHINGTON · PI Mari Ostendorf · 2012 to 2026
$201.8M
Novel Gene Editing Approaches for HemoglobinopathiesR01HL136135 · NHLBI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI HANS-PETER KIEM · 2017 to 2026
$7.7M
PedGeneRx - Admin Supplement to Base Editing and Prime Editing for Sickle Cell Disease R01R01HL156647 · NHLBI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Agnieszka Czechowicz, DAVID R LIU · 2021 to 2026
$4.8M
Targeting a Novel Hematopoietic Stem Cell Population in Non-Human Primates for Effective and Sustained Gene TherapyR01AI135953 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI KIEM, HANS-PETER · 2018 to 2022
$4.5M
In vivo precision genome editing to correct genetic diseaseR00HL163805 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI NEWBY, GREGORY A. · 2023 to 2025
Sickle cell disease (SCD) is caused by a single nucleotide change in the β-globin gene that adenine base editors can convert to the nonpathogenic Makassar β-globin variant. Here, we evaluated the long-term efficiency and off-target editing potential of autologous Makassar base editing in three rhesus macaques as a step toward human translation. Base editing of CD34
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Engraftment and persistence of · full record | OpenQuestion